Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Rutgers, UMDNJ research provides insight into fighting viruses

By Drug Discovery Trends Editor | September 30, 2011

Double-Stranded RNA

Structure of human RIG-I bound to double-stranded RNA. Image: Joseph Marcotrigiano

Researchers at Rutgers and UMDNJ-Robert Wood
Johnson Medical
School have determined the structure
of a protein that is the first line of defense in fighting viral infections
including influenza, hepatitis C, West Nile,
rabies, and measles.

Principal investigators of the
study, “Structural basis of RNA recognition and activation by innate
immune receptor RIG-I,”
chosen for advanced online publication in Nature, say the research is key in
the development of broad-based drug therapies to combat viral infections.

“Understanding innate immunity to
viral infections is crucial to developing drugs that can fight viruses or
control inflammation,” says Joseph Marcotrigiano, assistant professor of chemistry and chemical biology at Rutgers who along
with Smita Patel, professor of biochemistry at Robert Wood Johnson Medical
School, are principal investigators on the newly released
study. “Having this foundation is extremely important.”

RIG-I is a receptor protein that
recognizes differences in molecular patterns in order to differentiate viral
RNA—the process during which virus particles makes new copies of themselves
within a host cell and can then infect other cells—from cellular RNA. What
researchers discovered is that viral RNA, as opposed to single-stranded
cellular RNA, is a double-stranded structure. This double-stranded difference
is the reason the RIG-I protein recognizes it and initiates a signal to induce
anti-immune and anti-inflammatory defenses within the cell.

Prior to this research, there was
little understanding on how RIG-I protein recognized the viral infections, says
Patel. Knowing. That it is due to the double-stranded molecular structure of
the viral RNA is critical because, he says, “a failure of RIG-I to
identify viral RNA can lead to alterations of the cell, including cell death,
inflammation, autoimmune diseases, and cancer.”

This is a first step, the
scientists say, in helping to develop therapies that interfere with a broad
variety of viral infections—a major breakthrough for millions of people who get
sick from viruses which cannot be treated effectively by current medication.

“This work provides unprecedented
insights on the molecular mechanism of viral RNA recognition by RIG-I,” says
Barbara Gerratana, who oversees enzyme catalysis grants at the National Institute of General Medical Sciences of
the National Institutes of Health. “As a
result, we have a deeper understanding of how the human body fights viral
infections and a structural basis of the development of new anti-viral
therapeutics.”

SOURCE


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50